PCRX Pacira BioSciences Inc
- Stocks
- Healthcare
- NASDAQ: PCRX
Price (delayed)
$21.85
Market cap
$981.78M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.77
Enterprise value
$1.31B
Relative Growth:
Rel. Growth:
15
Relative Strength:
Rel. Strength:
41
Relative Valuation:
Rel. Valuation:
26
Relative Profitability:
Rel. Profitability:
26
Pacira BioSciences, Inc.is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. The company's long-acting local
Highlights
Pacira BioSciences's gross profit has increased by 8% YoY
The company's gross margin rose by 6% YoY
The company's quick ratio has shrunk by 67% YoY and by 6% QoQ
Pacira BioSciences's EPS has decreased by 23% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.pacira.com
Key stats
What are the main financial stats of PCRX
Market
Valuations
Earnings
Shares outstanding
44.93M
Market cap
$981.78M
Enterprise value
$1.31B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.34
Price to sales (P/S)
1.41
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
631.41
EV/Sales
1.86
Revenue
$705.85M
Gross profit
$551.93M
Operating income
-$104.33M
Net income
-$127.46M
EBIT
-$87.91M
EBITDA
$2.08M
Free cash flow
$117.07M
Per share
Balance sheet
Liquidity
EPS
-$2.77
EPS diluted
-$2.77
Free cash flow per share
$2.58
Book value per share
$16.36
Revenue per share
$15.53
TBVPS
$24.07
Total assets
$1.54B
Total liabilities
$779.5M
Debt
$631.4M
Equity
$757.77M
Working capital
$432.45M
Debt to equity
0.83
Current ratio
2.38
Quick ratio
1.79
Net debt/EBITDA
159.17
Margins
Efficiency
Dividend
EBITDA margin
0.3%
Gross margin
78.2%
Net margin
-18.1%
Operating margin
-14.8%
Return on assets
-8.2%
Return on equity
-16.5%
Return on invested capital
-7.6%
Return on capital employed
-7.2%
Return on sales
-12.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PCRX stock price
How has the Pacira BioSciences stock price performed over time
Intraday
-2.63%
1 week
4%
1 month
-12.04%
1 year
26.45%
YTD
15.98%
QTD
-15.21%
Financial performance
How have Pacira BioSciences's revenue and profit performed over time
Revenue
$705.85M
Gross profit
$551.93M
Operating income
-$104.33M
Net income
-$127.46M
Gross margin
78.2%
Net margin
-18.1%
The company's operating income fell by 23% QoQ
The company's net income fell by 23% QoQ
PCRX's operating margin is down by 23% QoQ
Pacira BioSciences's net margin has decreased by 22% from the previous quarter
Price vs fundamentals
How does PCRX's price correlate with its fundamentals
Growth
What is Pacira BioSciences's growth rate over time
Valuation
What is Pacira BioSciences stock price valuation
P/E
N/A
P/B
1.34
P/S
1.41
EV/EBIT
N/A
EV/EBITDA
631.41
EV/Sales
1.86
Pacira BioSciences's EPS has decreased by 23% QoQ
PCRX's P/B is 48% below its 5-year quarterly average of 2.6 but 12% above its last 4 quarters average of 1.2
The equity has declined by 14% year-on-year and by 5% since the previous quarter
The price to sales (P/S) is 59% lower than the 5-year quarterly average of 3.4
The revenue has grown by 2.3% YoY
Efficiency
How efficient is Pacira BioSciences business performance
Pacira BioSciences's ROIC has plunged by 185% YoY and by 85% from the previous quarter
Pacira BioSciences's return on sales has shrunk by 175% YoY and by 76% QoQ
PCRX's ROE is down by 28% since the previous quarter
Pacira BioSciences's ROA has decreased by 24% from the previous quarter
Dividends
What is PCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PCRX.
Financial health
How did Pacira BioSciences financials performed over time
The total assets is 97% greater than the total liabilities
The company's quick ratio has shrunk by 67% YoY and by 6% QoQ
The current ratio has plunged by 65% YoY
Pacira BioSciences's debt is 17% less than its equity
The equity has declined by 14% year-on-year and by 5% since the previous quarter
Pacira BioSciences's debt to equity has increased by 12% YoY and by 3.8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.